BRD4 identified as key biomarker to prevent metastasis in castration-resistant prostate cancer

Written by Louis Gautier, Future Science Group

Researchers from the Boston University School of Medicine (MA, USA) recently demonstrated the potential of a BET bromodomain protein, BRD4, as a novel target to prevent metastasis in castration-resistant prostate cancer. Castration-resistant prostate cancer is a highly aggressive form of prostate cancer that frequently becomes metastatic, killing more than 31,000 American men per year. The standard treatment of androgen deprivation therapy can delay progression of the disease; however, acquired resistance to the therapy is common and patients frequently begin to progress without cure after 2–3 years of treatment. The team from Boston have long-studied the BET bromodomain family of proteins...

To view the full article, please register now for access

It's completely free